Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442395 | 1.00 | PRMT6 (0.57) | PRMT6SMN1; SMN2ALDH1A1TDP1CYP2D6 | |
| SCHEMBL31528239 | 0.98 | SMN1; SMN2 (0.58) | PRMT6SMN1; SMN2ALDH1A1TDP1CYP2D6 | |
| SCHEMBL7656309 | 0.98 | SMN1; SMN2 (0.58) | PRMT6SMN1; SMN2ALDH1A1TDP1CYP2D6 | |
| SCHEMBL31528286 | 0.87 | NCF1 (0.62) | SMN1; SMN2ALDH1A1KDM4EHRH3 | |
| SCHEMBL208910 | 0.87 | NCF1 (0.62) | SMN1; SMN2ALDH1A1KDM4EHRH3 | |
| SCHEMBL3771382 | 0.85 | ALDH1A1 (0.56) | PRMT6SMN1; SMN2ALDH1A1TDP1CYP2D6 | |
| SCHEMBL209815 | 0.85 | MC4R (0.57) | PRMT6HRH3 | |
| SCHEMBL2324451 | 0.85 | SIGMAR1 (0.57) | TDP1HRH3 | |
| SCHEMBL31528202 | 0.85 | MC4R (0.57) | PRMT6HRH3 | |
| SCHEMBL17538318 | 0.83 | HRH3 (0.59) | TDP1HRH3MBTD1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEIGENE, LTD. (KY) | 2025-04-22 | — | — | US | disclosed |
| EP-3921319-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| EP-3848375-B1 | METHODS OF PREPARING INTERMEDIATES FOR TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2023-06-01 | — | — | US | disclosed |
| CN-115043840-A | Methods for preparing TOLL-like receptor modulators | 吉利德科学公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-107074860-B | Methods for preparing TOLL-like receptor modulators | 吉利德科学公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2022-04-21 | — | — | US | disclosed |
| US-20130071354-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130071354-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8367670-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367670-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367670-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2010077613-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2009066060-A2 | 4-SUBSTITUTED-6-ISOPROPYL-BENZENE-1,3-DIOL COMPOUNDS AND THEIR USE | TOPOTARGET A/S (DK) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | PRMT6 3752/4885SMN1; SMN2 3154/4885ALDH1A1 3435/4885 |
| US-20230167117-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR9 | PRMT6 4110/4885SMN1; SMN2 884/4885ALDH1A1 1537/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | PRMT6 1855/4885SMN1; SMN2 1682/4885ALDH1A1 1253/4885 |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR3 | PRMT6 4164/4885SMN1; SMN2 948/4885ALDH1A1 1611/4885 |
| US-20230303512-A1 | MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF | MYB, MYBBP1A, MYCBP | PRMT6 432/4885SMN1; SMN2 3479/4885ALDH1A1 4244/4885 |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR1, TLR3 | PRMT6 4164/4885SMN1; SMN2 948/4885ALDH1A1 1611/4885 |
| US-20130071354-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | PRMT6 3752/4885SMN1; SMN2 3154/4885ALDH1A1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.